Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateAtea Pharmaceuticals, Inc. (NASDAQ: AVIR) recently issued a press release detailing its financial results for the third quarter ending September 30, 2024, a

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Atea Pharmaceuticals’s 8K filing here.

Atea Pharmaceuticals Company Profile

(Get Free Report)

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.

Further Reading